Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 19:04:34·⟳ 抓取 19:06:25 +1m51s·⚡ 决策 10-19 19:10:48 +4m23s·8.2 天前
Xencor预告10月26日ESMO口头报告XmAb819肾癌I期数据，本次无任何疗效新数据
该文是对10月26日ESMO数据披露的提前日程通知，不含任何临床结果；口头报告入选本身公司已于2026-07-17官宣，属旧闻重播。真正的可交易催化是7天后的数据本身，方向（数据好坏）此刻不可知，提前一周做多/做空均无正期望。
📄 原文Investing.com↗ 原文
Xencor to present phase 1 data for kidney cancer treatment
Oil prices dip as Trump waives Russia sanctions PASADENA, Calif. - Xencor Inc. (NASDAQ:XNCR) will host a webcast on Oct…
不做 Xencor, Inc.（XNCR.US）
无增量事实：本条为10月26日ESMO数据披露的日程预告、不含疗效结果，且口头报告安排7月17日已官宣；真实催化（数据好坏）在7天后，方向不可知，现在无edge，待数据公布再研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Xencor仅预告10月26日将公布XmAb819肾癌I期数据，本条无疗效数字且报告日程7月已公开，无新增信息；应等数据落地再交易，现在不做。
消息传播链
- 节点
关键理由
- 无新增利好或利空事实：真实ORR/安全性数据要到2026-10-26才公布，当前无法确立方向
主要风险
- 10月26日数据可能显著超预期或不及预期，提前布局等于无信息裸博二元临床事件
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-19 · 影响 none
未检索到任何I期疗效结果提前泄露或公布，无可支撑当下做多的正面事实
检索:Xencor XmAb819 Phase 1 efficacy data ENPP3 renal results 原文 ↗
先例如何影响了这次决策
对本次决策的影响:支持在数据公布前AVOID
方向:不适用：本条无数据、非可交易催化，故不构建临床数据披露先例；待10月26日实际数据时再做对齐研究
涨幅量级:无可校准幅度
形态:无
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`xencor xmab819 phase 1 renal cell carcinoma esmo 2026 presentation | xncr xmab819 enpp3 bispecific data october 26 webcast`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - web_search 成功 doubao_search · 1,550 ms
豆包搜索结果（原始查询:Xencor XmAb819 ESMO 2026 Phase 1 renal cell carcinoma data presentation；API SearchType:web）
原文全文
展开原文 · 1,858 字
Oil prices dip as Trump waives Russia sanctions
PASADENA, Calif. - Xencor Inc. (NASDAQ:XNCR) will host a webcast on October 26 at 7:00 a.m. EDT to discuss results from a Phase 1 study of XmAb819, an experimental bispecific antibody being developed for patients with advanced clear cell renal cell carcinoma.
The company will present data from the Phase 1 study during an oral presentation at the European Society for Medical Oncology Congress 2026 in Madrid, Spain on Sunday. Dr. Sumanta Pal from City of Hope Comprehensive Cancer Center will present the findings during a session on genitourinary tumors scheduled for 8:30 a.m. to 10:00 a.m. CET.
XmAb819 is a T-cell engaging bispecific antibody that targets ENPP3, a protein with high-level expression in renal cell carcinoma and low-level expression on normal tissues. The treatment is being evaluated in a Phase 1 clinical study for patients with advanced clear cell renal cell carcinoma and ENPP3-positive tumors.
According to the press release statement, expansion cohorts are currently evaluating intravenous doses to support selection of a dose for a planned Phase 3 study. Dose escalation of subcutaneous administration in advanced clear cell renal cell carcinoma is ongoing.
The company opened a sub-study in the second quarter of 2026 for patients with ENPP3-positive advanced colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma. Another sub-study opened in the third quarter of 2026 for patients with intermediate- or poor-risk advanced clear cell renal cell carcinoma who progressed after first-line immunotherapy treatment.
Xencor plans to initiate a registration-enabling study of XmAb819 monotherapy in advanced clear cell renal cell carcinoma in 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
PASADENA, Calif. - Xencor Inc. (NASDAQ:XNCR) will host a webcast on October 26 at 7:00 a.m. EDT to discuss results from a Phase 1 study of XmAb819, an experimental bispecific antibody being developed for patients with advanced clear cell renal cell carcinoma.
The company will present data from the Phase 1 study during an oral presentation at the European Society for Medical Oncology Congress 2026 in Madrid, Spain on Sunday. Dr. Sumanta Pal from City of Hope Comprehensive Cancer Center will present the findings during a session on genitourinary tumors scheduled for 8:30 a.m. to 10:00 a.m. CET.
XmAb819 is a T-cell engaging bispecific antibody that targets ENPP3, a protein with high-level expression in renal cell carcinoma and low-level expression on normal tissues. The treatment is being evaluated in a Phase 1 clinical study for patients with advanced clear cell renal cell carcinoma and ENPP3-positive tumors.
According to the press release statement, expansion cohorts are currently evaluating intravenous doses to support selection of a dose for a planned Phase 3 study. Dose escalation of subcutaneous administration in advanced clear cell renal cell carcinoma is ongoing.
The company opened a sub-study in the second quarter of 2026 for patients with ENPP3-positive advanced colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma. Another sub-study opened in the third quarter of 2026 for patients with intermediate- or poor-risk advanced clear cell renal cell carcinoma who progressed after first-line immunotherapy treatment.
Xencor plans to initiate a registration-enabling study of XmAb819 monotherapy in advanced clear cell renal cell carcinoma in 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
06a8a5b44d· 2026-10-19 19:10 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前